Code Name: BlueSpot, a Go AI, is disclosed ahead of the handicap-match events in the 10th-anniversary year of the historic AlphaGo–Lee Sedol match.

NEW YORK, Jan. 15, 2026 /PRNewswire/ — Issued by Code Name: BlueSpot Operations

 

BlueSpot’s Handicap-Game Opening BlueSpot’s Handicap-Game Opening

Code Name: BlueSpot, the Go AI that embodies novel technology, is introduced today at the dawn of the 10th-anniversary year of the historic AlphaGo–Lee Sedol match.

As the milestone year begins to unfold, planning is underway for a Handicap-Adjustment Series as the main event—a series of public matches between BlueSpot and top-tier professional Go players. The intent is straightforward: to offer a clear perspective on the current discourse around AI—particularly the "AI bubble" narrative and its underlying assumptions—and to place demonstrable performance above private, unverifiable claims.

As a preliminary step, an Open Test—not a closed evaluation—in handicap-adjustment format is being prepared for the first half of 2026 (targeting March). It will be live-streamed online, feature multiple professional players drawn from a disclosed ranking range, and proceed under official refereeing. The venue will be announced in late January; final venue arrangements are underway across a small set of East Asian host locations.

BlueSpot is presented at this stage only as a code name. Further details will be disclosed with the main event. For the latest updates, visit https://codenamebluespot.com (Short link: https://cblue.spot).

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Pioneer Insurance Selects Sapiens to Drive Digital Innovation in the Philippines

Sapiens Insurance Platform for P&C supports Pioneer’s broad digital strategy and ability…

Xinhua Silk Road: NE. China-located ice city hails opening of frozen wonderland on Wednesday

BEIJING, Dec. 17, 2025 /PRNewswire/ — As the winter chill set in,…

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

CHENGDU, China, June 12, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162)…